

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of )  
J. Talley, et al. ) Attorney Docket No. 2779/16  
Serial No. TBA )  
Filed: November 3, 2003 ) Group Art Unit: TBA  
Examiner: TBA

For SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE  
TREATMENT OF INFLAMMATION

November 3, 2003

Assistant Commissioner of Patents  
Alexandria, VA


SIR:

**INFORMATION DISCLOSURE STATEMENT**

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicants submit herewith the attached Form PTO 1449. These documents were cited in a related application and are not resubmitted herewith. Applicants direct the Examiner to the related application number 10/125,325 for documents previously submitted. Applicants respectfully request that the Examiner consider and enter all the documents cited on the enclosed Form PTO 1449 into the file of the above-identified application. Applicants also request an indication of the same by return of the Form PTO 1449 being initialed and dated by the Examiner.

If any fees are required or an overpayment of fees made, the Commissioner is hereby authorized to debit or credit our Deposit Account No. 19-1025, as necessary.

Respectfully submitted,

  
James M. Warner, Reg. No. 45,199  
Attorney for Applicants  
(314) 274-3642

Pharmacia Corporation  
Corporate Patent Department  
P.O. Box 1027  
St. Louis, Missouri 63006

Customer No. 26648

<b>FORM PTO-1449</b>		U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 2779/16	APPLICATION NO.: TBA
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				INVENTOR: Talley, et al.	
				(Use several sheets if necessary)	
				Filed: November 3, 2003	Group: TBA

**U.S. PATENT DOCUMENTS**

Examiner Initial		Document Number							Date	Name	Class	Subclass	Filing Date If Appropriate
	<b>A1</b>	5	1	3	4	1	4	2	7/28/92	Matsuo, et al.			
	<b>A2</b>	4	1	4	6	7	2	1	3/27/79	George Rainer			
	<b>A3</b>	5	3	1	5	0	1	2	5/24/94	Connolly, et al.			
	<b>A4</b>	3	9	4	0	4	1	8	2/24/76	Robert Hamilton			
	<b>A5</b>	5	3	8	7	6	9	3	2/7/95	Connolly, et al.			
	<b>A6</b>	5	5	1	0	4	9	6	4/23/96	Talley, et al.			
	<b>A7</b>	5	5	0	4	2	1	5	4/12/96	Talley, et al.			
	<b>A8</b>	5	5	2	1	2	0	7	5/28/96	Talley, et al.			
	<b>A9</b>	5	4	6	6	8	2	3	11/14/95	Talley, et al.			
	<b>A10</b>	6	1	5	6	7	8	1	12/5/00	Talley, et al.			
	<b>A11</b>	5	7	5	3	6	8	8	5/19/98	Talley, et al.			
	<b>A12</b>	5	5	6	3	1	6	5	10/8/96	Talley, et al.			
	<b>A13</b>	5	5	0	8	4	2	6	4/16/96	Talley, et al.			
	<b>A14</b>	5	5	1	6	9	0	7	5/14/96	Talley, et al.			
	<b>A15</b>	5	7	6	0	0	6	8	6/2/98	Talley, et al.			
*	<b>A16</b>	5	8	9	2	0	5	3	4/6/99	Zhi, et al.			

**FOREIGN PATENT DOCUMENTS**

Examiner Initial		Document Number							Date	Country	Class	Subclass	Translation	
		EP	5	5	4	8	2	9					Yes	No
	<b>B1</b>	EP	5	5	4	8	2	9	8/11/93	Europe				
	<b>B2</b>	EP	3	4	7	7	7	3	12/27/89	Europe				
	<b>B3</b>	EP	4	7	7	0	4	9	3/25/92	Europe				
	<b>B4</b>	WO	94	1	4	7	7	7	7/7/94	International				
	<b>B5</b>	AU	94	7	5	7	5	3	10/12/93	Australia				

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>FORM PTO-1449</b> U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 2779/16	APPLICATION NO.: TBA
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		INVENTOR: Talley, et al.	
(Use several sheets if necessary)		Filed: November 3, 2003	Group: TBA

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

Examiner Initial		
	<b>C1</b>	R. Soliman et al., J. Pharm. Sci., 76, 626 (1987)
	<b>C2</b>	H. Mokhtar, Pak. J. Sci. Ind. Res., 31, 762 (1988)
	<b>C3</b>	H. Mokhtar et al., Pak. J. Sci. Ind. Res., 34, 9 (1991)
	<b>C4</b>	M. Cocco et al, II. Farmaco-Ed. Sci., 40, 272 (1985)
	<b>C5</b>	R. Soliman et al, J. Pharm. Sci., 72, 1004 (1983)
	<b>C6</b>	H. Feid-Allah, Pharmazie, 36, 754 (1981)
	<b>C7</b>	R. Soliman et al, J. Pharm. Sci., 70, 602 (1981)
	<b>C8</b>	Maybridge Chemical Co./Ryan Scientific Catalog, Compound No. BTB 06812
	<b>C9</b>	H. Mokhtar et al, Pak. J. Sci. Ind. Res., 33:30-36 (1990)
	<b>C10</b>	H. Mokhtar et al, J. Chem. Soc. Pak., 10:414-424 (1988)
	<b>C11</b>	R. Soliman et al, J. Pharm. Sci., 72:999-1004 (1983)
	<b>C12</b>	M. S. I. Makki et al, Chem. Abstracts, 121:134017 (1994)
	<b>C13</b>	R. Hamilton, J. Heterocyclic Chem., 13, 545 (1976)
	<b>C14</b>	M. Hashem et al, J. Med. Chem., 19, 229 (1976)
	<b>C15</b>	H. Feid-Allah, J. Heterocyclic Chem., 18, 1561 (1981)
	<b>C16</b>	H. Mokhtar et al, Pharmazie, 33, 649 (1978)
	<b>C17</b>	R. Soliman et al, Pharmazie, 33 (1978)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	